Current NHS consultant posts held
Dr Sarker is a Senior Lecturer and Honorary Consultant in Medical Oncology at Guy’s and St Thomas’ NHS Foundation Trust, and King’s College Hospital NHS Foundation Trust
Research interests
Dr Sarker's main research focus is in the development of novel therapies for cancer, and together with Dr James Spicer, runs the Early Phase Clinical Trials Unit based at Guy’s Hospital. He is also actively involved in the management of hepato-pancreatic-biliary malignancies at King’s College Hospital Liver Unit, and has a specific interest in the development of new therapies and molecular imaging for these tumours.
Publications
Mohd Noor A, Sarker D, Vizor S, McLennan B, Hunter S, Suder A, Moller H, Spicer JF, Papa S. Effect of patient socioeconomic status on access to early-phase cancer trials. J Clin Oncol. 2013 Jan 10;31(2):224-30.
Goh V, Sarker D, Osmany S, Cook GJ. Functional imaging techniques in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):1070-9
Brunetto AT, Sarker D, Papadatos-Pastos D, Fehrmann R, Kaye SB, Johnston S, Allen M, De Bono JS, Swanton C. A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit. Br J Cancer 2010;103(5):607-12
Middleton MR, Knox R, Cattell E, Oppermann U, Midgley R, Ali R, Auton T, Agarwal R, Anderson D, Sarker D, Judson I et al., Quinone oxidoreductase-2 mediated prodrug cancer therapy. Sci Transl Med 2010; 2, 40ra50
Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, Papadopoulou A, Bell J, Kayani I, Toumpanakis C, Grillo F, Mayer A, Hochhauser D, Begent RH, Caplin ME, Meyer T. Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.Br J Cancer 2010; 102(7):1106-12
Banerji U, Camidge DR, Verheul HMW, Agarwal R, Sarker D, Kaye SB, Desar IM, Timmer-Bonte JN, Eckhardt SG, Lewis KD, Brown KH, Cantarini MV, Morris C, George SM, Smith PD, van Herpen CM. The first-in-human study of the hydrogen sulfate (Hyd-Sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a Phase I open-label multicentre trial in patients with advanced cancer. Clin Cancer Res 2010;16(5):1613-23
Carden C, Sarker D, Yap T, Postel-Vinay S, Attard G, Banerji U, Garrett M, Thomas G, Workman P, Kaye S, de Bono JS. Can Molecular Biomarker-Based Patient Selection In Phase I Trials Accelerate Anticancer Drug Development? Drug Discov Today 2010;15(3-4):88-97
Sarker D, Reid A, Yap T, de Bono JS. Targeting the PI3Kinase pathway in prostate cancer. Clin Cancer Res 2009;15(15):4799-805
